Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.

@article{Welch2011CombinationDA,
  title={Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.},
  author={John S. Welch and Jeffery M Klco and Feng Gao and Elizabeth Procknow and Geoffery L Uy and K Stockerl-Goldstein and Camille N. Abboud and Peter J. Westervelt and John F. DiPersio and Anjum Hassan and Amanda Cashen and Ravi Vij},
  journal={American journal of hematology},
  year={2011},
  volume={86 9},
  pages={
          796-800
        }
}
Childhood immune thrombocytopenia (ITP) has a favorable outcome in most cases but severe bleeding may occur, mostly in children with very low platelet counts. Although first-line therapies are well defined, management of refractory ITP is not consensual. Vinblastine (VBL) is one second-line treatment in adult series. We reported all childhood refractory ITP treated with VBL in our unit in past 10 years. VBL was administered by four weekly injections (6 mg/m/ dose) in initial phase, followed by… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Is the combinational administration of doxorubicin and glutathione a reasonable proposal?

  • Acta Pharmacologica Sinica
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2017
VIEW 2 EXCERPTS
CITES RESULTS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 92 REFERENCES

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 33 EXCERPTS
HIGHLY INFLUENTIAL

VEGF targeted therapy in acute myeloid leukemia.

  • Critical reviews in oncology/hematology
  • 2011
VIEW 25 EXCERPTS
HIGHLY INFLUENTIAL

Epigenetic therapy in myelodysplastic syndromes.

  • European journal of haematology
  • 2010
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…